Evidence map›Paper›PMID 32578153›Full record

ArticleInvestigational new drugs2021

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

Frank Kroschinsky, Jan Moritz Middeke, Martin Janz, Georg Lenz, Mathias Witzens-Harig, Reda Bouabdallah, Paul La Rosée, Andreas Viardot, Gilles Salles, Seok Jin Kim and 8 more

Open access · bronzeAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigational new drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 14 institutions in 6 countries.

Frank KroschinskyMedical Department I, University Hospital at the Technical University of Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Jan Moritz MiddekeMedical Department I, University Hospital at the Technical University of Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Martin JanzExperimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Robert-Rössle-Straße 10, 13125, Berlin, Germany.
Georg LenzDepartment of Hematology and Oncology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
Mathias Witzens-HarigInternal Medicine V: Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 672, 69120, Heidelberg, Germany.
Reda BouabdallahDepartment ofHematology, Institute Paoli Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.
Paul La RoséeKlinik für Innere Medizin II, Universitätsklinikum, Jena, Germany.
Andreas ViardotDepartment of Internal Medicine III, University Hospital of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany.
Gilles SallesDepartment of Hematology, University Hospital of South Lyon, 165 Chemin du Grand Revoyet, 69310, Pierre-Bénite, France.
Seok Jin KimDivision of Haematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Irwon-dong, Gangnam-gu, Seoul, South Korea.
Tae Min KimDepartment of Internal Medicine, Seoul National University Hospital, 101 Daehak-Ro Jongno-Gu, Seoul, 03080, South Korea.
Oliver OttmannDivision of Cancer and Genetics, Department of Haematology, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
Joerg ChromikUniversitätsklinikum Frankfurt, Johann-Wolfgang-Goethe-Universität, Theodor-W.-Adorno-Platz 1, 60323, Frankfurt, Germany.
Anne-Marie QuinsonBoehringer Ingelheim Pharmaceuticals Inc., 900 Ridgebury Road, Ridgefield, CT, 06877, USA.
Ute von WangenheimBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riß, Germany.
Ute BurkardBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397, Biberach an der Riß, Germany.
Andreas BerkClinTriCare GmbH & Co. KG, Untere Illereicher Str. 10, 89281, Altenstadt, Germany.
Norbert SchmitzDepartment of Hematology and Oncology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany. Norbert.Schmitz@ukmuenster.de.ORCID https://orcid.org/0000-0003-4938-7528
Boehringer Ingelheim (Germany) · DETechnische Universität Dresden · DEUniversity Hospital Münster · DEBoehringer Ingelheim (United States) · USCancer Research Institute · USCardiff University · GBGoethe University Frankfurt · DEHeidelberg University · DEHôpital Lyon Sud · FRInstitut Paoli-Calmettes · FRJena University Hospital · DEMax Delbrück Center · DESamsung Medical Center · KRUniversity Hospital Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID32578153
PMCPMC8025277
OpenAlexW3032251732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.